Rain Enhancement Technologies Holdco, Inc.
RAINW - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$1.03M
Close$
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $1.03 Million |
|---|---|
| Enterprise Value | $1.11 Million |
| Earnings per Share | $-1.2 |
| Beta | -0.22 |
| Outstanding Shares | 7,829,921 |
Return
| Return on Equity | 96.76% |
|---|---|
| Return on Assets | -487.41% |
| Return on Invested Capital | 93.64% |
Valuation & Multiples
| P/E Ratio | -0.44 |
|---|---|
| PEG | -0.18 |
| Price to Sales | - |
| Price to Book Ratio | -0.07 |
| Enterprise Value to Revenue | 105.81 |
| Enterprise Value to EBIT | -0.11 |
| Enterprise Value to Net Income | -1 |
| Total Debt to Enterprise | 0.1 |
| Debt to Equity | -0.01 |
Revenue Sources
No data
Institutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
About Rain Therapeutics Inc
4 employees
CEO: Randall Seidl
Rain Therapeutics Inc. is a clinical-stage precision oncology company developing therapies that target oncogenic drivers for which it is able to genetically select patients it believes will most likely benefit. This approach includes usi...